NCT05324488Recruiting
Diabetes Registry Graz for Biomarker Research
Source: ClinicalTrials.gov · Last updated 7 Jul 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The Diabetes registry for biomarker research Graz is a prospective cohort-study including subjects with type 1 and type 2 diabetes, rare types of diabetes, obesity and dyslipidemia, aiming to collect data, blood and urine samples of all subjects on an annual basis.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2000 (estimated)
- First submitted
- 29 Sept 2021
- Start date
- 21 Oct 2015
- Primary completion date
- 1 Jan 2035
- Lead sponsor
- Medical University of Graz
- Diseases
- Type 2 diabetes
- NCT number
- NCT05324488
What you commit to
- Study type: Observational
- Planned participants: 2000
- From 21 Oct 2015 to the primary completion date, 1 Jan 2035
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- No written informed consent
- No willingness to participate in this registry
Who the study is looking for
- 18 - 99 years
- Informed consent has to be given in written form
- At least one of the following diseases:
- Type 1 diabetes
- Type 2 diabetes
- Type 3 diabetes
- Maturity onset diabetes of young (MODY)
- Late onset diabetes of the adult (LADA)
- Adipositas (BMI \> 30kg/m2)
- Lipid metabolism disorder
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medical University of Graz Coordinator of this site? Confirm its status | Graz | Austria | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.